Kisspeptin and Leptin as Treatments for Functional Hypothalamic Ammenorhea (FHA): Experimental Approach or Emerging Therapy?
DOI:
https://doi.org/10.12775/QS.2026.49.67123Keywords
leptin, functional hypothalamic amenorrhea, kisspeptin, reproduction, hypothalamic-pituitary-gonadal axisAbstract
Functional hypothalamic amenorrhea (FHA) is a common cause of amenorrhea among women in reproductive age. The disturbance is often associated with stress and deficiency in energy availability caused by either intensive exercise or improper nutrition. Those factor affect the hypothalamic-pituitary-gonadal axis and further absence of ovulation and normal menstrual cycle. Treatment should be directed to treatment of the etiology, however sometimes it is not enough.
For this reason, novel therapies emerged to counteract the consequences of FHA to support restoring that lifestyle changes are not capable of. This review summarizes current knowledge on the leptin and kisspeptin treatment, which recently gained more interest, due to it physiological basis in hypothalamic-pituitary-gonadal axis. Furthermore, paper evaluates clinical data, its limitations and safety consideration, and more importantly, the need for future research.
References
[1] R. E. Roberts, L. Farahani, L. Webber, and C. Jayasena, ‘Current understanding of hypothalamic amenorrhoea’, Therapeutic Advances in Endocrinology, vol. 11, p. 2042018820945854, Jan. 2020, doi: 10.1177/2042018820945854.
[2] C. M. Gordon et al., ‘Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline’, The Journal of Clinical Endocrinology & Metabolism, vol. 102, no. 5, pp. 1413–1439, May 2017, doi: 10.1210/jc.2017-00131.
[3] ‘The Female Athlete Triad’, Medicine & Science in Sports & Exercise, vol. 39, no. 10, pp. 1867–1882, Oct. 2007, doi: 10.1249/mss.0b013e318149f111.
[4] S. L. Berga et al., ‘Neuroendocrine Aberrations in Women With Functional Hypothalamic Amenorrhea*’, The Journal of Clinical Endocrinology & Metabolism, vol. 68, no. 2, pp. 301–308, Feb. 1989, doi: 10.1210/jcem-68-2-301.
[5] B. Męczekalski et al., ‘Neuroendocrine disturbances in women with functional hypothalamic amenorrhea: an update and future directions’, Endocrine, vol. 84, no. 3, pp. 769–785, Dec. 2023, doi: 10.1007/s12020-023-03619-w.
[6] D. S. Miller, R. R. Reid, N. S. Cetel, R. W. Rebar, and S. S. Yen, ‘Pulsatile administration of low-dose gonadotropin-releasing hormone. Ovulation and pregnancy in women with hypothalamic amenorrhea’, JAMA, vol. 250, no. 21, pp. 2937–2941, Dec. 1983.
[7] S. Andrico, ‘Leptin in functional hypothalamic amenorrhoea’, Human Reproduction, vol. 17, no. 8, pp. 2043–2048, Aug. 2002, doi: 10.1093/humrep/17.8.2043.
[8] E. Sowińska-Przepiera et al., ‘Czynnościowy podwzgórzowy brak miesiączki – trudności diagnostyczne, monitorowanie i leczenie’, Endokrynologia Polska, vol. 66, no. 3, pp. 252–268, Jul. 2015, doi: 10.5603/EP.2015.0033.
[9] K. Klejc et al., ‘Psychosocial stress in women with functional hypothalamic amenorrhea and potential implications for cardiovascular disease risk’, Stress, vol. 28, no. 1, p. 2589533, Dec. 2025, doi: 10.1080/10253890.2025.2589533.
[10] M. D. Marcus, T. L. Loucks, and S. L. Berga, ‘Psychological correlates of functional hypothalamic amenorrhea’, Fertility and Sterility, vol. 76, no. 2, pp. 310–316, Aug. 2001, doi: 10.1016/S0015-0282(01)01921-5.
[11] E. Hrabovszky, ‘Neuroanatomy of the human hypothalamic kisspeptin system’, Neuroendocrinology, vol. 99, no. 1, pp. 33–48, 2014, doi: 10.1159/000356903.
[12] Q. Xie et al., ‘The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction’, Front Endocrinol (Lausanne), vol. 13, p. 925206, 2022, doi: 10.3389/fendo.2022.925206.
[13] F. Bacopoulou et al., ‘Serum kisspeptin concentrations are negatively correlated with body mass index in adolescents with anorexia nervosa and amenorrhea’, Hormones (Athens), vol. 16, no. 1, pp. 33–41, Jan. 2017, doi: 10.14310/horm.2002.1717.
[14] T. Hofmann et al., ‘Plasma kisspeptin and ghrelin levels are independently correlated with physical activity in patients with anorexia nervosa’, Appetite, vol. 108, pp. 141–150, Jan. 2017, doi: 10.1016/j.appet.2016.09.032.
[15] J.-A. P. De Bond and J. T. Smith, ‘Kisspeptin and energy balance in reproduction’, REPRODUCTION, vol. 147, no. 3, pp. R53–R63, Mar. 2014, doi: 10.1530/REP-13-0509.
[16] C. F. Elias and D. Purohit, ‘Leptin signaling and circuits in puberty and fertility’, Cell Mol Life Sci, vol. 70, no. 5, pp. 841–862, Mar. 2013, doi: 10.1007/s00018-012-1095-1.
[17] J. Donato et al., ‘Leptin’s effect on puberty in mice is relayed by the ventral premammillary nucleus and does not require signaling in Kiss1 neurons’, J Clin Invest, vol. 121, no. 1, pp. 355–368, Jan. 2011, doi: 10.1172/JCI45106.
[18] G. V. Childs, A. K. Odle, M. C. MacNicol, and A. M. MacNicol, ‘The Importance of Leptin to Reproduction’, Endocrinology, vol. 162, no. 2, p. bqaa204, Feb. 2021, doi: 10.1210/endocr/bqaa204.
[19] V. Speirs, G. P. Skliris, S. E. Burdall, and P. J. Carder, ‘Distinct expression patterns of ER and ER in normal human mammary gland’, Journal of Clinical Pathology, vol. 55, no. 5, pp. 371–374, May 2002, doi: 10.1136/jcp.55.5.371.
[20] A. B. Khalid and S. A. Krum, ‘Estrogen receptors alpha and beta in bone’, Bone, vol. 87, pp. 130–135, Jun. 2016, doi: 10.1016/j.bone.2016.03.016.
[21] J. L. Yang, E. Hodara, I. Sriprasert, D. Shoupe, and F. Z. Stanczyk, ‘Estrogen deficiency in the menopause and the role of hormone therapy: integrating the findings of basic science research with clinical trials’, Menopause, vol. 31, no. 10, pp. 926–939, Oct. 2024, doi: 10.1097/GME.0000000000002407.
[22] K. E. Friday, B. L. Drinkwater, B. Bruemmer, C. Chesnut, and A. Chait, ‘Elevated plasma low-density lipoprotein and high-density lipoprotein cholesterol levels in amenorrheic athletes: effects of endogenous hormone status and nutrient intake’, J Clin Endocrinol Metab, vol. 77, no. 6, pp. 1605–1609, Dec. 1993, doi: 10.1210/jcem.77.6.8263148.
[23] B. Ahmed et al., ‘Diabetes mellitus, hypothalamic hypoestrogenemia, and coronary artery disease in premenopausal women (from the National Heart, Lung, and Blood Institute sponsored WISE study)’, Am J Cardiol, vol. 102, no. 2, pp. 150–154, Jul. 2008, doi: 10.1016/j.amjcard.2008.03.029.
[24] C. Shufelt, T. Torbati, and E. Dutra, ‘Hypothalamic Amenorrhea and the Long-Term Health Consequences’, Semin Reprod Med, vol. 35, no. 03, pp. 256–262, May 2017, doi: 10.1055/s-0037-1603581.
[25] M. E. Nelson, E. C. Fisher, P. D. Catsos, C. N. Meredith, R. N. Turksoy, and W. J. Evans, ‘Diet and bone status in amenorrheic runners’, Am J Clin Nutr, vol. 43, no. 6, pp. 910–916, Jun. 1986, doi: 10.1093/ajcn/43.6.910.
[26] B. M. Biller, J. F. Coughlin, V. Saxe, D. Schoenfeld, D. I. Spratt, and A. Klibanski, ‘Osteopenia in women with hypothalamic amenorrhea: a prospective study’, Obstet Gynecol, vol. 78, no. 6, pp. 996–1001, Dec. 1991.
[27] R. Indirli, V. Lanzi, G. Mantovani, M. Arosio, and E. Ferrante, ‘Bone health in functional hypothalamic amenorrhea: What the endocrinologist needs to know’, Front Endocrinol (Lausanne), vol. 13, p. 946695, 2022, doi: 10.3389/fendo.2022.946695.
[28] C. Workman, D. V. Blalock, and P. S. Mehler, ‘Bone density status in a large population of patients with anorexia nervosa’, Bone, vol. 131, p. 115161, Feb. 2020, doi: 10.1016/j.bone.2019.115161.
[29] P. C. Bendis, S. Zimmerman, A. Onisiforou, P. Zanos, and P. Georgiou, ‘The impact of estradiol on serotonin, glutamate, and dopamine systems’, Front Neurosci, vol. 18, p. 1348551, 2024, doi: 10.3389/fnins.2024.1348551.
[30] M. P. Warren et al., ‘Persistent osteopenia in ballet dancers with amenorrhea and delayed menarche despite hormone therapy: a longitudinal study’, Fertil Steril, vol. 80, no. 2, pp. 398–404, Aug. 2003, doi: 10.1016/s0015-0282(03)00660-5.
[31] K. L. Cobb et al., ‘The effect of oral contraceptives on bone mass and stress fractures in female runners’, Med Sci Sports Exerc, vol. 39, no. 9, pp. 1464–1473, Sep. 2007, doi: 10.1249/mss.0b013e318074e532.
[32] C. K. Welt et al., ‘Recombinant human leptin in women with hypothalamic amenorrhea’, N Engl J Med, vol. 351, no. 10, pp. 987–997, Sep. 2004, doi: 10.1056/NEJMoa040388.
[33] K. Dobranowska, S. Plińska, and A. Dobosz, ‘Dietary and Lifestyle Management of Functional Hypothalamic Amenorrhea: A Comprehensive Review’, Nutrients, vol. 16, no. 17, p. 2967, Sep. 2024, doi: 10.3390/nu16172967.
[34] L. Cialdella-Kam, C. Guebels, G. Maddalozzo, and M. Manore, ‘Dietary Intervention Restored Menses in Female Athletes with Exercise-Associated Menstrual Dysfunction with Limited Impact on Bone and Muscle Health’, Nutrients, vol. 6, no. 8, pp. 3018–3039, Jul. 2014, doi: 10.3390/nu6083018.
[35] S. H. Chou et al., ‘Leptin is an effective treatment for hypothalamic amenorrhea’, Proc Natl Acad Sci U S A, vol. 108, no. 16, pp. 6585–6590, Apr. 2011, doi: 10.1073/pnas.1015674108.
[36] E. Sienkiewicz et al., ‘Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women’, Metabolism, vol. 60, no. 9, pp. 1211–1221, Sep. 2011, doi: 10.1016/j.metabol.2011.05.016.
[37] W. S. Dhillo et al., ‘Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males’, J Clin Endocrinol Metab, vol. 90, no. 12, pp. 6609–6615, Dec. 2005, doi: 10.1210/jc.2005-1468.
[38] W. S. Dhillo et al., ‘Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women’, J Clin Endocrinol Metab, vol. 92, no. 10, pp. 3958–3966, Oct. 2007, doi: 10.1210/jc.2007-1116.
[39] C. N. Jayasena et al., ‘Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis’, J Clin Endocrinol Metab, vol. 94, no. 11, pp. 4315–4323, Nov. 2009, doi: 10.1210/jc.2009-0406.
[40] C. N. Jayasena et al., ‘Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea’, Clin Pharmacol Ther, vol. 88, no. 6, pp. 840–847, Dec. 2010, doi: 10.1038/clpt.2010.204.
[41] C. N. Jayasena et al., ‘Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of Kisspeptin-54’, J Clin Endocrinol Metab, vol. 99, no. 6, pp. E953-961, Jun. 2014, doi: 10.1210/jc.2013-1569.
[42] A. Abbara et al., ‘Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders’, J Clin Invest, vol. 130, no. 12, pp. 6739–6753, Dec. 2020, doi: 10.1172/JCI139681.
[43] E. G. Mills et al., ‘Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans’, EBioMedicine, vol. 115, p. 105689, May 2025, doi: 10.1016/j.ebiom.2025.105689.
[44] Metreleptin (Myalepta): CADTH Reimbursement Recommendation. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2024.
[45] J. Zammouri et al., ‘Molecular and Cellular Bases of Lipodystrophy Syndromes’, Front Endocrinol (Lausanne), vol. 12, p. 803189, 2021, doi: 10.3389/fendo.2021.803189.
[46] M. W. Haymond et al., ‘The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges’, Orphanet J Rare Dis, vol. 18, no. 1, p. 127, May 2023, doi: 10.1186/s13023-023-02714-5.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Malgorzata Bednarczyk, Michał Karol, Kamila Koseska, Jan Borowicz, Bartosz Górecki, Kinga Kloch, Patryk Romaniuk, Mariia-Khrystyna Lohin, Aleksandra Strawińska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 52
Number of citations: 0
